Predictive model using four ferroptosis-related genes accurately predicts gastric cancer prognosis

Figure 6 Correlation of hub genes with immune infiltration and immunotherapy. A: Correlation between NOX4 and immune cells; B: Correlation between MTCH1 and immune cells; C: Correlation between GABARAPL2 and immune cells; D: Correlation between SLC2A3 and immune cells; E: Differences in the ratios of immune cells between the high- and low-risk groups in the cancer genome atlas of stomach adenocarcinoma (TCGA-STAD) cohort; F: Different expression levels of immune checkpoint proteins between the high- and low-risk groups in the TCGA-STAD cohort. ^aP < 0.05, ^bP < 0.01, ^cP < 0.001. NK cell: Natural killer cell; Th1: Type 1 T helper; Th2: Type 2 T helper; iDC: Interdigitating dendritic cells; pDC: Pre-dendritic cells; aDC: Activated dendritic cells; TFH: T-follicular helper; VTCN1: T-cell activation inhibitor-1; PDCD1: Programed cell death 1; TIGIT: T cell immunoreceptor with Ig and ITIM domains; TMIGD2: Transmembrane and immunoglobulin (Ig) domain containing 2; TNFSF9: Tumor necrosis factor superfamily member 9; LAIR1: Leukocyte-associated immunoglobulin-like receptor 1; BTLA: B- and T-lymphocyte attenuator; HAVCR2: Hepatitis A virus cellular receptor; 2LAG3: Lymphocyte activating gene 3.